Toxicity and effectivity of high-dose Idarubicin during AML induction therapy: Results of a pilot study in children
U. Creutzig, D. Körholz, C. M. Niemeyer, H. Kabisch, N. Graf, A. Reiter, H. Scheel-Walter, C. Bender-Götze, W. Behnisch, J. Hermann, G. Mann, J. Ritter, M. Zimmermann · Klinische Pädiatrie · 2000 · Heft 04 · S. 163-168
Bibliografische Angaben
Zusammenfassung
Summary. BACKGROUND: Idarubicin (IDR) is one of the most effective, but also toxic drugs in the treatment of AML. The standard dose used in children and adults is 8 - 12 mg/m2 during induction. PATIENTS AND METHODS: To improve outcome, we increased the IDR dose from 12 mg/m2 (standard dose in study AML-BFM 93), applied over three days during induction therapy (AIE=Ara-C, Idarubicin, Etoposide) to 14 mg/m2 in a pilot study including 17 patients (16 with de novo AML, one with secondary AML). Outcome and toxicities were compared with the other patients of study AML-BFM 93, treated with 3 × 12 mg/m2 IDR or 6 × 30 mg…
